



ZIOPHARM Oncology, Inc.  
 Investor Relations Department  
 One First Ave., Parris Building, # 34  
 Navy Yard Plaza  
 Boston, MA 02199  
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

**NASDAQ: ZIOP**

Last Trade:	5.20
Trade Time:	10:34 AM ET Aug 22, 2017
Change:	0.16 (+3.175%)
Day Range	5.05 - 5.28
52-Week Range	4.84 - 7.88
Volume	217,363


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Jul 31, 2017*  
[ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities](#)
- Jul 24, 2017*  
[ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET](#)
- Jun 28, 2017*  
[ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma](#)
- Jun 5, 2017*  
[ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting](#)
- Jun 2, 2017*  
[ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference](#)

**Financials** [\[ View all \]](#)

- Feb 16, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Jul 31, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016*  
[Quarterly Report \(10-Q\)](#)